Imaging techniques for assessing liver fibrosis are advancing. This Clinical Outlook article discusses the best practices and reviews emerging options for magnetic resonance and ultrasound-based elastography.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Zhang, Y. N. et al. Liver fibrosis imaging: a clinical review of ultrasound and magnetic resonance elastography. J. Magn. Reson. Imaging 51, 25–42 (2020).
Schambeck, J. P. L. et al. Diagnostic accuracy of magnetic resonance elastography and point-shear wave elastography for significant hepatic fibrosis screening: systematic review and meta-analysis. PLoS ONE 18, e0271572 (2023).
Selvaraj, E. A. et al. Diagnostic accuracy of elastography and magnetic resonance imaging in patient with NAFLD: a systematic review and meta-analysis. J. Hepatol. 75, 770–785 (2021).
Guo, Y. et al. Magnetic resonance elastography and acoustic radiation force impulse for staging hepatic fibrosis: a meta-analysis. Abdom. Imaging 40, 818–834 (2015).
Zhang, Y. N. et al. Comparative diagnostic performance of ultrasound shear wave elastography and magnetic resonance elastography for classifying fibrosis stage in adults with biopsy-proven nonalcoholic fatty liver disease. Eur. Radiol. 32, 2457–2469 (2022).
Jung, J. et al. MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis. Gut 70, 1946–1953 (2021).
Sanyal, A. J. et al. Non-invasive biomarkers of nonalcoholic steatohepatitis: the FNIH NIMBLE project. Nat. Med. 28, 430–432 (2022).
Singh, S. et al. Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 11, 1573–1584.e2 (2013).
Andersson, A. et al. Clinical utility of magnetic resonance imaging biomarkers for identifying nonalcoholic steatohepatitis patients at high risk of progression: a multicenter pooled data and meta-analysis. Clin. Gastroenterol. Hepatol. 20, 2451–2461.e3 (2022).
Pirasteh, A. et al. Staging liver fibrosis by fibroblast activation protein inhibitor PET in a human-sized swine model. J. Nucl. Med. 63, 1956–1961 (2022).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
K.J.F. declares grant support from Bayer, Median, Pfizer, GE and Siemen and personal consulting for Bayer, GE and Ascelia pharmaceutical, and is a Liver Imaging Reporting and Data System steering committee member. M.R.B. declares grant support from Siemens Healthineers, Madrigal, Carmot Therapeutics, Corcept Therapeutics, NGM biopharmaceuticals, Bayer and Metacrine Inc. and is a Liver Imaging Reporting and Data System steering committee member.
Rights and permissions
About this article
Cite this article
Fowler, K.J., Bashir, M.R. The current status of imaging in liver fibrosis. Nat Rev Gastroenterol Hepatol 20, 628–629 (2023). https://doi.org/10.1038/s41575-023-00833-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41575-023-00833-9
